The single biggest issue for the industry are the failed Ph3 programmes for drug classes like CETP inhibitors and anti-amyloids.
FORBES: Are We The Problem? The Role Of Poor Decision-Making In Stifling Drug Development
应用推荐
模块上移
模块下移
不移动